Biocon Biologics announced that Shreehas Tambe has been promoted to the position of Deputy Chief Executive Officer of Biocon Biologics w.e.f. March 1, 2021.

A Biocon veteran, Shreehas joined Biocon in 1997 and has, since then, taken on positions of increasing responsibility. He has over 20 years of leadership experience in operational and strategic roles and has led large, diverse teams at R&D, Manufacturing and Projects and Engineering during his tenure. Shreehas began his professional journey at Biocon as a management trainee starting out in the R&D department, where he led the design and development of a novel bioreactor, the PlaFractor, a unique solid state bioreactor that got Biocon its first US patent and went on to win the National Award for the Best Technology of
the Year in 2001.

Prior to becoming the Deputy CEO, Shreehas was the Chief Operating Officer and a key
member of the Executive Leadership Team at Biocon Biologics. Previously, as the Senior Vice President and Global Head of Biocon’s Insulins business unit he was responsible for the P&L and expanding the Insulins portfolio across several geographies. He led the development,
approval and launch of Insulin analogs in Japan and later in EU and US. The insulins franchise showed strong performance in emerging markets led by sales in Mexico, Malaysia and Latin America.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics, said, “I am delighted to welcome Shreehas Tambe in his new role as the Deputy CEO of Biocon Biologics. During his more than two decade-long career with Biocon, Shreehas has exhibited strong leadership in his diverse roles at R&D, Manufacturing and Projects and Engineering. Shreehas has also worked closely with Dr Arun Chandavarkar, Managing Director of Biocon Biologics, on formulating business strategies and achieving operational excellence. I believe the combination of Arun and Shreehas in their new roles along with the rest of the leadership team will enable Biocon
Biologics to capitalise on the promising biosimilars opportunity to pursue its high growth trajectory.”

Dr Arun Chandavarkar, Managing Director, Biocon Biologics said, “I would like to
congratulate Shreehas Tambe for his new role as the Deputy CEO of Biocon Biologics. Shreehas has played a critical role in shaping our biosimilars business over the years in different roles and more recently as the COO of Biocon Biologics. As a key member of the various committees
looking at governance, investments and strategic collaborations, Shreehas has leveraged his domain knowledge and the technical and functional expertise to contribute towards making Biocon Biologics a global leader. Biocon Biologics is built on strong business fundamentals and
I am confident Shreehas will use his expertise and leadership skills to enable his teams to deliver robust growth and reaffirm their commitment to impact millions of patients’ lives globally.”

Shreehas Tambe, Deputy Chief Executive Officer, Biocon Biologics said, “I am deeply
honored to take on this role to drive Biocon Biologics towards becoming a global leader in affordable healthcare. I am humbled by the faith placed in me by Biocon Biologics’ leadership and the Board members. Along with the leadership team, I am looking forward to realising the several opportunities that lie ahead of us and work collaboratively to address challenges.
We have a proven track record of scientific credibility, global scale, highest standards of quality and governance, which give me the confidence that along with our partners and customers we will successfully deliver on our vision to make healthcare accessible to benefit millions of patients and their families across the world.”

It was under Shreehas’ leadership that Biocon made its first overseas investment in R&D and manufacturing in 2015, building Asia’s largest integrated insulins complex in Malaysia, which is approved by the US FDA and EMA among other regulatory agencies. Shreehas was the Global Head of Projects and Engineering when he led the multi-million dollar investment in Malaysia, managing and providing strategic direction to the investment.

He holds a Masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences and Technology at University of Pune. He was conferred the coveted Distinguished Alumnus Award (Professional) by his alma mater, the prestigious ICT, Mumbai, in 2020.